Rituximab Increases Risk of Severe COVID-19 in Patients with Rheumatic Disease
Patients with inflammatory rheumatic and musculoskeletal diseases on rituximab therapy may have a greater risk for severe COVID-19, according to a study.
“In particular, rituximab...
Etanercept vs. Methotrexate: How Do These Drugs Compare in RA Patients in Remission?
Among patients with rheumatoid arthritis (RA) who have achieved remission following combination methotrexate plus etanercept, monotherapy with etanercept was superior to methotrexate, according to...
Rheum Round-up: Disease Activity Affects COVID-19 Death, CRF and Mortality in RA, and more
Disease Activity, DMARDs May Affect COVID-19 Death Risk in Patients With Rheumatic Disease
In addition to known risk factors, including older age and certain comorbidities,...
Reduced Cardiorespiratory Fitness Mediates Excess All-cause Mortality in Rheumatoid Arthritis
A study found that low cardiorespiratory fitness (CRF) was a mediator of excess all-cause mortality among patients with rheumatoid arthritis (RA) and suggested that...
Risk for Rheumatoid Arthritis Reduced for Patients With T2DM
TUESDAY, Feb. 23, 2021 (HealthDay News) -- Patients with type 2 diabetes mellitus (T2DM) have a reduced risk for rheumatoid arthritis (RA), which may...
Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?
An analysis of two studies comparing adalimumab biosimilar SDZ-ADL versus reference adalimumab in patient-reported outcomes (PROs) in patients with moderate‐to‐severe chronic plaque psoriasis (PsO),...
Dr. Nowell Discusses Which PROs Are Most Important To Rheumatology Patients
Benjamin Nowell, Ph.D, Director of Patient-Centered Research, CreakyJoints, and principal investigator of ArthritisPower, discusses the results of a new study, “Which patient-reported outcomes do...
